Skip to main
MAZE

MAZE Stock Forecast & Price Target

MAZE Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 43%
Buy 57%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Maze Therapeutics Inc., a clinical-stage biopharmaceutical firm focused on advancing precision medicines for chronic kidney disease, is making significant strides with its lead programs, MZE829 and MZE782, showcasing strong efficacy signals in early trials that could facilitate accelerated regulatory approval. The company's innovative Compass platform enhances its ability to link genetic variants to disease pathways, reinforcing confidence in the potential commercial success of its therapies as the updated ICD-10-CM codes support improved diagnosis and treatment. Furthermore, positive Phase 1 data for MZE782 demonstrates a favorable pharmacokinetic profile and substantial increases in urinary Phe excretion, indicating possible best-in-class positioning and enhancing the company's overall market outlook.

Bears say

Maze Therapeutics Inc. is currently facing significant challenges that contribute to a negative outlook on its stock performance. The company’s investigational drug inaxaplin, linked to observed declines in estimated glomerular filtration rate (eGFR), raises concerns regarding its efficacy, potentially inflating efficacy signals and leading to risk assessments suggesting a potential ~30% downside. Additionally, the adverse effects in patients, including inadequate responses to current prevalent therapies like SGLT2 inhibitors, coupled with the limitations in patient stabilization during clinical evaluations, highlight the uncertainties surrounding the company's therapeutic potential and overall market viability.

MAZE has been analyzed by 7 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 57% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Maze Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Maze Therapeutics Inc (MAZE) Forecast

Analysts have given MAZE a Buy based on their latest research and market trends.

According to 7 analysts, MAZE has a Buy consensus rating as of Mar 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $58.71, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $58.71, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Maze Therapeutics Inc (MAZE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.